All In Biotech

Drug Trial Radar · NCT07891312

Amisulpride Injection for the Prevention of Postoperative Nausea and Vomiting in Patients Undergoing Laparoscopic Surgery

An Interventional, Randomized Controlled, Single-blind, Multicenter Clinical Study Evaluating the Efficacy and Safety of Amisulpride Injection for the Prevention of Postoperative Nausea and Vomiting in Patients Undergoing Laparoscopic Surgery.

Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 718 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

718

Planned (sponsor's estimate)

Start

Nov 15, 2026

Primary completion

Jan 1, 2028

Study completion Feb 2028

Sponsor

Lead sponsor
Qianfoshan HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 23, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a randomized controlled clinical trial focusing on the prevention of postoperative nausea and vomiting (PONV), planned to start in May 2026 and end in April 2027. It primarily compares the efficacy and safety of amisulpride injection combined with ondansetron versus ondansetron alone in patients undergoing laparoscopic surgery. A centralized stratified block randomization method will be used. In the combination group, patients will receive a single intravenous injection of amisulpride 5 mg plus ondansetron 4 mg within 1-2 minutes after anesthesia induction, while the control group will receive ondansetron 4 mg alone. The study adopts a single-blind design, meaning that patients will not know their group assignment. The primary objective is to evaluate the efficacy of the combination regimen in preventing PONV under different anesthesia methods. The primary endpoint is complete response (CR), defined as no vomiting or retching and no use of rescue antiemetic medication within 24 hours after surgery. Secondary endpoints include the incidence of nausea at 2, 6, 12, and 24 hours postoperatively, the proportion of patients with significant nausea (VAS \>4), the incidence of vomiting, and the proportion requiring rescue medication. The study will also assess safety, as well as the effects of the combination regimen on emergence agitation, postoperative delirium, shivering, recovery of bowel function, changes in inflammatory factors, postoperative pain, and analgesic consumption. The study population consists of patients undergoing elective laparoscopic surgery under general anesthesia. After providing informed consent, eligible participants will undergo baseline assessment, including demographic information, medical history, PONV risk factors, comorbidities, medication history, vital signs, electrocardiogram, and laboratory tests. Postoperatively, blinded assessors will collect PONV-related information during the periods of 0-2 hours, 2-6 hours, and 6-24 hours, and will also record vital signs, adverse events, and concomitant medications. The primary efficacy endpoint will be assessed within 24 hours after surgery, while safety follow-up will usually continue until postoperative day 7 or discharge. Sample size was calculated based on the primary endpoint of CR. According to previous studies, the expected CR rate is about 57% in the combination group and 46% in the ondansetron-alone group. Using a two-independent-sample proportion difference test with a two-sided alpha of 0.05 and beta of 0.20, 323 participants are required per group. Allowing for a 10% dropout rate, 359 participants will be enrolled in each group, for a total of 718 participants. In terms of study management, the protocol clearly defines criteria for study completion, dropout, and early withdrawal. The study will be considered complete when the last participant has finished the day-7 telephone follow-up or early withdrawal visit, and all data cleaning, review, and statistical analyses have been completed. Reasons for withdrawal include withdrawal of informed consent, loss to follow-up, death, study termination by the investigator, as well as early discontinuation due to adverse events, intolerable toxicity, or major protocol deviations. Data management emphasizes authenticity, completeness, and traceability. Demographic data, vital signs, laboratory tests, and ECG findings may be directly entered into the case report form (CRF). Data such as nausea scores, shivering grades, agitation/delirium assessments, pain scores, bowel function recovery, and drug administration records must first be documented in source records before being transcribed into the CRF. Statistical analyses will be performed using SAS version 9.4 or above. Both an efficacy analysis set and a safety analysis set will be defined. Analyses will be stratified by anesthesia method, with methods including stratified chi-square tests, repeated-measures analysis of variance, and t-tests, while also exploring the independent effects after adjustment for confounding factors such as age, sex, duration of surgery, and anesthesia method. Overall, the study is relatively well designed, with clear randomization procedures, a well-defined primary endpoint, a reasonable sample size calculation, and a fairly complete plan for safety evaluation, statistical analysis, and data management. It is expected to provide clinically valuable evidence on the use of amisulpride combined with ondansetron for the prevention of PONV.

Conditions

  • PONV

Interventions

  • AmisulprideDrug

    Amisulpride 5 mg, single intravenous injection

  • OndansetronDrug

    Ondansetron 4 mg, single intravenous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The primary endpoint is complete response (CR), defined as the absence of any vomiting or retching and no use of rescue antiemetic medication within 24 hours postoperatively.Time frame: 24 hours

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.